{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:24:07Z","timestamp":1779189847300,"version":"3.51.4"},"reference-count":129,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1097\/crd.0000000000000044","type":"journal-article","created":{"date-parts":[[2014,10,12]],"date-time":"2014-10-12T23:28:18Z","timestamp":1413156498000},"page":"109-118","source":"Crossref","is-referenced-by-count":23,"title":["Pathophysiologic and Treatment Strategies for Cardiovascular Disease in End-Stage Renal Disease and Kidney Transplantations"],"prefix":"10.1097","volume":"23","author":[{"given":"Mythili","family":"Ghanta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Kozicky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda","family":"Jim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1681\/ASN.V133745","article-title":"Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States.","volume":"13","author":"Muntner","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2004030203","article-title":"Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.","volume":"16","author":"Foley","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1681\/ASN.2010050459","article-title":"The increasing prevalence of atrial fibrillation among hemodialysis patients.","volume":"22","author":"Winkelmayer","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000441-200304000-00002","article-title":"Cardiovascular mortality in end-stage renal disease.","volume":"325","author":"Collins","year":"2003","journal-title":"Am J Med Sci"},{"key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.90.3.1129","article-title":"Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, andor kaliuresis in humans.","volume":"90","author":"Vesely","year":"1994","journal-title":"Circulation"},{"key":"R8-1-20210203","first-page":"29","article-title":"Importance of volume factors in dialysis related hypertension.","volume":"48","author":"Lins","year":"1997","journal-title":"Clin Nephrol"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/ajh\/7.11.1016","article-title":"Sustained volume expansion and Na,KATPase inhibition in chronic renal failure.","volume":"7","author":"Glatter","year":"1994","journal-title":"Am J Hypertens"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.ki.5000266","article-title":"Physiological changes during hemodialysis in patients with intradialysis hypertension.","volume":"69","author":"Chou","year":"2006","journal-title":"Kidney Int"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(01)07217-8","article-title":"Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.","volume":"358","author":"Zoccali","year":"2001","journal-title":"Lancet"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2215\/CJN.05040908","article-title":"Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA).","volume":"4","author":"Krapf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0272-6386(99)70413-0","article-title":"Mechanism of erythropoietin-induced hypertension.","volume":"33","author":"Vaziri","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1046\/j.1525-139x.2000.00040.x","article-title":"The overlooked role of salt restriction in dialysis patients.","volume":"13","author":"Mailloux","year":"2000","journal-title":"Semin Dial"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0272-6386(97)90199-2","article-title":"Dialysate sodium delivery can alter chronic blood pressure management.","volume":"29","author":"Flanigan","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"R16-1-20210203","first-page":"831","article-title":"Interdialysis blood pressure control by long haemodialysis sessions.","volume":"10","author":"Chazot","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1056\/NEJMoa1001593","article-title":"FHN Trial Group. In-center hemodialysis six times per week versus three times per week.","volume":"363","author":"Chertow","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0025-7125(05)70583-6","article-title":"Nonpharmacologic approaches to hypertension. Weight, sodium, alcohol, exercise, and tobacco considerations.","volume":"81","author":"Reisin","year":"1997","journal-title":"Med Clin North Am"},{"key":"R19-1-20210203","first-page":"337","article-title":"Profile of antihypertensive drugs in hypertensive patients on renal replacement therapy (RRT).","volume":"48","author":"Zazgornik","year":"1997","journal-title":"Clin Nephrol"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1161\/01.CIR.82.1.105","article-title":"Salt and water retention and calcium blockade in uremia.","volume":"82","author":"London","year":"1990","journal-title":"Circulation"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1093\/ndt\/14.12.2803","article-title":"Not all left ventricular hypertrophy is created equal.","volume":"14","author":"Klingbeil","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ndt\/12.5.945","article-title":"ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure.","volume":"12","author":"Dyadyk","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/0140-6736(90)92904-V","article-title":"Angiotensin-converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis.","volume":"336","author":"Verresen","year":"1990","journal-title":"Lancet"},{"key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2165\/00003088-199324030-00005","article-title":"Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.","volume":"24","author":"Hoyer","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II.","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1046\/j.1523-1755.1998.06825.x","article-title":"Evaluation of the Losartan in Hemodialysis (ELHE) Study.","volume":"68","author":"Saracho","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(05)65816-3","article-title":"Cardiovascular disease in patients with chronic renal failure.","volume":"348","author":"Wheeler","year":"1996","journal-title":"Lancet"},{"key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/S0021-9258(18)61656-4","article-title":"Transport of beta-very low density lipoproteins and chylomicron remnants by macrophages is mediated by the low density lipoprotein receptor pathway.","volume":"262","author":"Ellsworth","year":"1987","journal-title":"J Biol Chem"},{"key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/01.ATV.19.10.2474","article-title":"Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins.","volume":"19","author":"Cohn","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R32-1-20210203","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1161\/01.CIR.99.22.2852","article-title":"Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis.","volume":"99","author":"Hodis","year":"1999","journal-title":"Circulation"},{"key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1681\/ASN.2007101128","article-title":"Lipid abnormalities and cardiovascular risk in renal disease.","volume":"19","author":"Ritz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2008.11.007","article-title":"Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.","volume":"153","author":"Moradi","year":"2009","journal-title":"Transl Res"},{"key":"R35-1-20210203","first-page":"276","article-title":"Commonly measured laboratory variables in hemodialysis patients: relationships among them and to death risk.","volume":"12","author":"Lowrie","year":"1992","journal-title":"Semin Nephrol"},{"key":"R36-1-20210203","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"R37-1-20210203","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"R38-1-20210203","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/j.ajkd.2011.05.026","article-title":"Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie).","volume":"58","author":"Drechsler","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R39-1-20210203","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"R40-1-20210203","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1681\/ASN.2004080656","article-title":"Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study.","volume":"16","author":"Muntner","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R41-1-20210203","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.2215\/CJN.09961110","article-title":"Committee of Renal Data Registry, Japanese Society for Dialysis Therapy. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients.","volume":"6","author":"Shoji","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R42-1-20210203","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.2215\/CJN.04320709","article-title":"Coronary calcification in patients with chronic kidney disease and coronary artery disease.","volume":"4","author":"Nakamura","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R43-1-20210203","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJM197403282901301","article-title":"Accelerated atherosclerosis in prolonged maintenance hemodialysis.","volume":"290","author":"Lindner","year":"1974","journal-title":"N Engl J Med"},{"key":"R44-1-20210203","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2215\/CJN.03980609","article-title":"European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients.","volume":"4","author":"Barreto","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R45-1-20210203","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000098542","article-title":"Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients.","volume":"27","author":"Taki","year":"2007","journal-title":"Am J Nephrol"},{"key":"R46-1-20210203","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2215\/CJN.05340610","article-title":"Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress.","volume":"6","author":"Yu","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"R47-1-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1900\/RDS.2010.7.275","article-title":"Increased levels of total P-Cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy.","volume":"7","author":"Chiu","year":"2010","journal-title":"Rev Diabet Stud"},{"key":"R48-1-20210203","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/ndt\/gfp592","article-title":"European Uraemic Toxin Work Group (EUTox). Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease.","volume":"25","author":"Liabeuf","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R49-1-20210203","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/ki.2008.31","article-title":"Free p-cresol is associated with cardiovascular disease in hemodialysis patients.","volume":"73","author":"Meijers","year":"2008","journal-title":"Kidney Int"},{"key":"R50-1-20210203","doi-asserted-by":"crossref","first-page":"H1143","DOI":"10.1152\/ajpheart.01237.2010","article-title":"Chronic renal failure alters endothelial function in cerebral circulation in mice.","volume":"301","author":"Bugnicourt","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R51-1-20210203","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1681\/ASN.2012080875","article-title":"ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients.","volume":"24","author":"Maduell","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"R52-1-20210203","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfg414","article-title":"Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.","volume":"18","author":"London","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R53-1-20210203","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1681\/ASN.2007080854","article-title":"Mechanisms of vascular calcification in chronic kidney disease.","volume":"19","author":"Moe","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R55-1-20210203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11906-012-0265-8","article-title":"Vascular calcification: pathophysiology and risk factors.","volume":"14","author":"Chen","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"R57-1-20210203","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"key":"R58-1-20210203","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/BF03346443","article-title":"Cardiovascular aspects of primary hyperparathyroidism.","volume":"31","author":"Walker","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"R59-1-20210203","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1210\/jc.2009-1086","article-title":"Carotid vascular abnormalities in primary hyperparathyroidism.","volume":"94","author":"Walker","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R60-1-20210203","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.ehj.2003.09.010","article-title":"Parathyroid hormone and left ventricular hypertrophy.","volume":"24","author":"Saleh","year":"2003","journal-title":"Eur Heart J"},{"key":"R61-1-20210203","doi-asserted-by":"crossref","first-page":"F1215","DOI":"10.1152\/ajprenal.00406.2006","article-title":"Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways.","volume":"292","author":"Rashid","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"R62-1-20210203","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000069761","article-title":"Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells.","volume":"26","author":"Perkovic","year":"2003","journal-title":"Kidney Blood Press Res"},{"key":"R63-1-20210203","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1172\/JCI118582","article-title":"1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes.","volume":"97","author":"Wu","year":"1996","journal-title":"J Clin Invest"},{"key":"R64-1-20210203","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5414\/CNP71207","article-title":"Cinacalcet reduces vascular and soft tissue calcification in secondary hyperparathyroidism (SHPT) in hemodialysis patients.","volume":"71","author":"Aladren Regidor","year":"2009","journal-title":"Clin Nephrol"},{"key":"R65-1-20210203","doi-asserted-by":"crossref","first-page":"F1376","DOI":"10.1152\/ajprenal.90737.2008","article-title":"The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats.","volume":"296","author":"Lopez","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"R66-1-20210203","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/ndt\/gfh834","article-title":"1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (SensiparMimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.","volume":"20","author":"Henley","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R67-1-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1740774511399128","article-title":"The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.","volume":"8","author":"Pritchett","year":"2011","journal-title":"Clin Trials"},{"key":"R68-1-20210203","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"R69-1-20210203","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"R70-1-20210203","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1523-1755.2004.00425.x","article-title":"Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients.","volume":"65","author":"Li","year":"2004","journal-title":"Kidney Int"},{"key":"R71-1-20210203","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"R72-1-20210203","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2012.76","article-title":"The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.","volume":"82","author":"Coyne","year":"2012","journal-title":"Kidney Int"},{"key":"R73-1-20210203","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia.","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"R74-1-20210203","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease.","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"R75-1-20210203","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"R76-1-20210203","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0140-6736(00)02783-5","article-title":"Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial.","volume":"356","author":"Boaz","year":"2000","journal-title":"Lancet"},{"key":"R77-1-20210203","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.CIR.0000050628.11305.30","article-title":"The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial.","volume":"107","author":"Tepel","year":"2003","journal-title":"Circulation"},{"key":"R78-1-20210203","first-page":"CD008176","article-title":"Antioxidants for chronic kidney disease.","volume":"10","author":"Jun","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R79-1-20210203","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"R80-1-20210203","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1097\/TP.0b013e3181fecfcb","article-title":"Induction immunosuppression improves long-term graft and patient outcome in organ transplantation: an analysis of United Network for Organ Sharing registry data.","volume":"90","author":"Cai","year":"2010","journal-title":"Transplantation"},{"key":"R81-1-20210203","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/TP.0b013e3181caeead","article-title":"Reduction in cardiovascular death after kidney transplantation.","volume":"89","author":"Pilmore","year":"2010","journal-title":"Transplantation"},{"key":"R82-1-20210203","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199610150-00025","article-title":"Kidney transplant recipients who die with functioning grafts: serum creatinine level and cause of death.","volume":"62","author":"West","year":"1996","journal-title":"Transplantation"},{"key":"R83-1-20210203","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-6143.2009.02949.x","article-title":"PORT Investigators. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study.","volume":"10","author":"Israni","year":"2010","journal-title":"Am J Transplant"},{"key":"R84-1-20210203","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1432-2277.2012.01488.x","article-title":"PORT Investigators. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant.","volume":"25","author":"Israni","year":"2012","journal-title":"Transpl Int"},{"issue":"suppl 1","key":"R85-1-20210203","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12023","article-title":"OPTNSRTR 2011 Annual Data Report: heart.","volume":"13","author":"Colvin-Adams","year":"2013","journal-title":"Am J Transplant"},{"key":"R86-1-20210203","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1681\/ASN.2004070580","article-title":"Incidence and predictors of myocardial infarction after kidney transplantation.","volume":"16","author":"Lentine","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R87-1-20210203","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1111\/j.1600-6143.2012.04101.x","article-title":"Kidney function and risk of cardiovascular disease and mortality in kidney transplant recipients: the FAVORIT trial.","volume":"12","author":"Weiner","year":"2012","journal-title":"Am J Transplant"},{"key":"R88-1-20210203","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/TP.0b013e31821f303f","article-title":"Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients.","volume":"92","author":"Silver","year":"2011","journal-title":"Transplantation"},{"key":"R89-1-20210203","doi-asserted-by":"crossref","first-page":"E438","DOI":"10.1111\/j.1399-0012.2012.01676.x","article-title":"Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study.","volume":"26","author":"Carpenter","year":"2012","journal-title":"Clin Transplant"},{"key":"R90-1-20210203","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2012.05.008","article-title":"American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.","volume":"60","author":"Lentine","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R91-1-20210203","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1016\/j.transproceed.2013.09.013","article-title":"Metabolic syndrome performs better than the individual factors in predicting renal graft outcome.","volume":"45","author":"Mohsin","year":"2013","journal-title":"Transplant Proc"},{"key":"R92-1-20210203","doi-asserted-by":"crossref","first-page":"269096","DOI":"10.1155\/2013\/269096","article-title":"New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the UNOSOPTN database.","volume":"2013","author":"Yadav","year":"2013","journal-title":"J Transplant"},{"key":"R93-1-20210203","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1111\/j.1600-6143.2005.01104.x","article-title":"One-year post-transplant weight gain is a risk factor for graft loss.","volume":"5","author":"Ducloux","year":"2005","journal-title":"Am J Transplant"},{"key":"R95-1-20210203","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/TP.0b013e31826e592e","article-title":"Calcineurin inhibition and new-onset diabetes mellitus after transplantation.","volume":"95","author":"Chakkera","year":"2013","journal-title":"Transplantation"},{"key":"R96-1-20210203","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/SLA.0b013e318187d1da","article-title":"Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.","volume":"248","author":"Woodle","year":"2008","journal-title":"Ann Surg"},{"key":"R97-1-20210203","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.transproceed.2013.11.057","article-title":"High prevalence of obesity in Thai renal transplant recipients: a multicenter study.","volume":"46","author":"Ruangkanchanasetr","year":"2014","journal-title":"Transplant Proc"},{"key":"R98-1-20210203","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.transproceed.2013.11.137","article-title":"Challenges for preventing the metabolic syndrome in kidney transplant recipients, initial report: survey of the current state of affairs before acting.","volume":"46","author":"Nakanome","year":"2014","journal-title":"Transplant Proc"},{"key":"R100-1-20210203","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.ajkd.2010.10.048","article-title":"Hypertension after kidney transplant.","volume":"57","author":"Mangray","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"R101-1-20210203","doi-asserted-by":"crossref","first-page":"121S","DOI":"10.1016\/0895-7061(96)00288-9","article-title":"Sympathetic neural mechanisms of cyclosporine-induced hypertension.","volume":"9","author":"Sander","year":"1996","journal-title":"Am J Hypertens"},{"key":"R102-1-20210203","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1681\/ASN.2007080911","article-title":"A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension.","volume":"19","author":"Goodwin","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R103-1-20210203","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.transproceed.2013.11.140","article-title":"Pathologic findings of renal biopsy were a helpful diagnostic clue of stenosis of the iliac segment proximal to the transplant renal artery: a case report.","volume":"46","author":"Aoyama","year":"2014","journal-title":"Transplant Proc"},{"key":"R104-1-20210203","doi-asserted-by":"crossref","first-page":"e000091","DOI":"10.1161\/JAHA.112.000091","article-title":"Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients.","volume":"2","author":"Aftab","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"R105-1-20210203","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/01.TP.0000437672.78716.28","article-title":"Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers.","volume":"97","author":"Opelz","year":"2014","journal-title":"Transplantation"},{"key":"R106-1-20210203","first-page":"809","article-title":"Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the early period after kidney transplantation.","volume":"37","author":"Orlic","year":"2013","journal-title":"Coll Antropol"},{"key":"R107-1-20210203","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1432-2277.2009.00922.x","article-title":"Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.","volume":"22","author":"Hillebrand","year":"2009","journal-title":"Transpl Int"},{"key":"R108-1-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/TP.0b013e3181a9e960","article-title":"Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials.","volume":"88","author":"Cross","year":"2009","journal-title":"Transplantation"},{"key":"R110-1-20210203","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.transproceed.2013.02.050","article-title":"Effect of daily sodium intake on post-transplant hypertension in kidney allograft recipients.","volume":"45","author":"Soypacaci","year":"2013","journal-title":"Transplant Proc"},{"key":"R111-1-20210203","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/j.1600-6143.2012.04084.x","article-title":"Dyslipidemia and its therapeutic challenges in renal transplantation.","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"R113-1-20210203","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","article-title":"The effects of glucocorticoids on adipose tissue lipid metabolism.","volume":"60","author":"Peckett","year":"2011","journal-title":"Metabolism"},{"key":"R114-1-20210203","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.transproceed.2011.03.015","article-title":"Dyslipidemia in human kidney transplant recipients receiving cyclosporine and tacrolimus is associated with different expression of CD36 on peripheral blood monocytes.","volume":"43","author":"Jiang","year":"2011","journal-title":"Transplant Proc"},{"key":"R115-1-20210203","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"R116-1-20210203","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study.","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"R117-1-20210203","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1016\/j.transproceed.2011.08.074","article-title":"Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.","volume":"43","author":"Spinelli","year":"2011","journal-title":"Transplant Proc"},{"key":"R118-1-20210203","first-page":"CD005019","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients.","volume":"1","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R119-1-20210203","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3109\/0886022X.2013.810540","article-title":"Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine.","volume":"35","author":"Scarfia","year":"2013","journal-title":"Ren Fail"},{"key":"R120-1-20210203","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00063030-199708050-00006","article-title":"Use of HMG-CoA reductase inhibitors after kidney and heart transplantation: lipid-lowering and immunosuppressive effects.","volume":"8","author":"Wanner","year":"1997","journal-title":"BioDrugs"},{"key":"R121-1-20210203","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0b013e31826c3968","article-title":"Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis.","volume":"94","author":"Cohen","year":"2012","journal-title":"Transplantation"},{"key":"R122-1-20210203","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.transproceed.2012.09.049","article-title":"Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.","volume":"44","author":"Paschoalin","year":"2012","journal-title":"Transplant Proc"},{"key":"R123-1-20210203","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.transproceed.2013.11.145","article-title":"Serum leptin levels positively correlate with peripheral arterial stiffness in kidney transplantation patients.","volume":"46","author":"Lee","year":"2014","journal-title":"Transplant Proc"},{"key":"R124-1-20210203","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1111\/j.1600-6143.2007.01903.x","article-title":"Determinants of coronary artery calcification progression in renal transplant recipients.","volume":"7","author":"Schankel","year":"2007","journal-title":"Am J Transplant"},{"key":"R125-1-20210203","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/ndt\/gfl021","article-title":"The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients.","volume":"21","author":"Yuen","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R126-1-20210203","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/TP.0b013e318160254f","article-title":"Risk factors for cardiovascular events after successful renal transplantation.","volume":"85","author":"Vanrenterghem","year":"2008","journal-title":"Transplantation"},{"key":"R127-1-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1600-6143.2011.03825.x","article-title":"Endogenous plasma erythropoietin, cardiovascular mortality and all-cause mortality in renal transplant recipients.","volume":"12","author":"Sinkeler","year":"2012","journal-title":"Am J Transplant"},{"key":"R128-1-20210203","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.amjcard.2006.11.055","article-title":"Anemia as a risk factor for kidney function decline in individuals with heart failure.","volume":"99","author":"Bansal","year":"2007","journal-title":"Am J Cardiol"},{"key":"R129-1-20210203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.transproceed.2008.09.063","article-title":"Preemptive living-donor renal transplantation: outcome and clinical advantages.","volume":"41","author":"Yoo","year":"2009","journal-title":"Transplant Proc"},{"issue":"suppl 1","key":"R130-1-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ajt.12579","article-title":"OPTNSRTR 2012 Annual Data Report: kidney.","volume":"14","author":"Matas","year":"2014","journal-title":"Am J Transplant"},{"key":"R131-1-20210203","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1053\/j.ajkd.2011.12.014","article-title":"Age and the associations of living donor and expanded criteria donor kidneys with kidney transplant outcomes.","volume":"59","author":"Molnar","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"R132-1-20210203","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/01.tp.0000190423.82154.01","article-title":"Chronic allograft nephropathy: current concepts and future directions.","volume":"81","author":"Nankivell","year":"2006","journal-title":"Transplantation"},{"key":"R133-1-20210203","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/TP.0b013e31820c10eb","article-title":"Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).","volume":"91","author":"Vanrenterghem","year":"2011","journal-title":"Transplantation"},{"key":"R134-1-20210203","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/ajt.12459","article-title":"Long-term exposure to belatacept in recipients of extended criteria donor kidneys.","volume":"13","author":"Charpentier","year":"2013","journal-title":"Am J Transplant"},{"key":"R135-1-20210203","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"R136-1-20210203","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/tri.12252","article-title":"SOCRATES Study Group. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients.","volume":"27","author":"Chadban","year":"2014","journal-title":"Transpl Int"},{"key":"R137-1-20210203","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1586\/1744666X.2014.872562","article-title":"The pros and the cons of mTOR inhibitors in kidney transplantation.","volume":"10","author":"Ponticelli","year":"2014","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T20:57:20Z","timestamp":1650401840000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-201505000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000044","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}